Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4611077 | 0.86 | LMNA (0.59) | ALDH1A1LMNAEPHX2MEN1KMT2A | |
| SCHEMBL4779105 | 0.84 | MEN1 (0.50) | ALDH1A1LMNAEPHX2MEN1KMT2A | |
| SCHEMBL27436851 | 0.81 | ALDH1A1 (0.61) | ALDH1A1LMNAEPHX2MEN1KMT2A | |
| SCHEMBL27437048 | 0.79 | ALDH1A1 (0.56) | ALDH1A1EPHX2MEN1KMT2AL3MBTL1 | |
| SCHEMBL31618421 | 0.78 | LMNA (0.50) | ALDH1A1LMNAEPHX2MEN1KMT2A | |
| SCHEMBL3712266 | 0.77 | LMNA (0.58) | ALDH1A1LMNAEPHX2MGAMGAA | |
| SCHEMBL3567423 | 0.77 | EPHX2 (0.65) | ALDH1A1LMNAEPHX2 | |
| SCHEMBL1073599 | 0.76 | ALDH1A1 (0.57) | ALDH1A1EPHX2MEN1KMT2AGAA | |
| SCHEMBL15189250 | 0.76 | MEN1 (0.51) | ALDH1A1LMNAEPHX2MEN1KMT2A | |
| SCHEMBL4611452 | 0.76 | ALDH1A1 (0.49) | ALDH1A1LMNAEPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1178969-B1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-07-13 | — | — | EP | disclosed |
| US-20030195240-A1 | Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-6479531-B1 | Gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1178969-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001085167-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PROTON PUMP INHIBITORS AND GASTRIN/CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2000027823-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195240-A1 | Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands | GIPR, CCKAR, CCKBR | ALDH1A1 4620/4885LMNA 3604/4885EPHX2 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.